Lenalidomide vs. Placebo for Multiple Myeloma Patients Following a Single ASCT
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
In the updated analysis, the current median follow up for overall survival (OS) was 65 months. When it was previously published, the OS was 34 months. The longer follow up has shown a significant improvement in time to progression for lenalidomide vs placebo.
The patients on the lenalidomide arm have not yet reached a median OS; these patients continue to do very well.
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
